natgillin/translations-raw huggingface dataset:
2.8 ml once daily
2,8 ml jednom dnevno
2.8 ml twice daily
2,3 ml dvaput dnevno
2.8 ml twice daily
2,8 ml dva puta dnevno
2.8 ml twice daily
2,8 ml dvaput dnevno
2.8 years.
2,8 godina.
2.8-fold increase
Povećanje od 2,8 puta
2.82B [2.17; 3.67]
3,98B [3,05; 5,18]
2.88 ml (Fill: 3.40 ml)
2,88 ml (Punjenje 3,40 ml)
2.9
GT1
2.9 (NR, NR)
2,9 (ND; ND)
2.9 HR 0.68; p=0.0129
HR 0,68; p= 0,0129
2.9 m vs 2.7 m
2,9 m vs 2,7 m
2.9 ml containing 1.45 mg fentanyl ensuring the delivery of 20 doses of 50 micrograms
2,9 ml sadrži 1,45 mg fentanila i osigurava unos 20 doza od 50 mikrograma.
2.9 ml containing 2.90 mg fentanyl ensuring the delivery of 20 doses of 100 micrograms
2,9 ml sadrži 2,90 mg fentanila i osigurava unos 20 doza od 100 mikrograma.
2.9 ml containing 5.80 mg fentanyl ensuring the delivery of 20 doses of 200 micrograms
2,9 ml sadrži 5,80 mg fentanila i osigurava unos 20 doza od 200 mikrograma.
2.9 months (95% CI: 2.8, 4.0)
2,9 mjeseci (95% CI: 2,8; 4,0)
2.9% (-13.7% to 19.6%)
2,9% (-13,7% do 19,6%)
2.If cytopenia is unrelated to leukaemia, reduce dose of Imatinib Accordto 400 mg.
Ako citopenija nije povezana s leukemijom, dozu Imatinib Accorda treba smanjiti na 400 mg.
2/3 or AIS
(41,1; 60,7)
2/88
Ostalo
20 (12, 31)
Parametar
20 (20x1) pre-filled syringe (multipack)
20 (20 x1) unaprijed napunjena štrcaljki (višestruko pakovanje)
20 (6)b
Dex n=312c
20 7%; P < .0001
20 7%; P < 0,0001
20 avenue Raymond Aron 92165 Antony Cedex France
20 avenue Raymond Aron 92165 Antony Cedex Francuska
20 avenue Raymond Aron F-92165 Antony Cedex France
20 avenue Raymond Aron F-92165 Antony Cedex Francuska
20 baits per square km over the areas where fox / raccoon dog density indexes were more than 3 foxes / raccoon dogs seen per 10 km.
20 mamca po kvadratnom kilometru na području na kojem je viđenost lisica/kunopasa veća od 3 lisice/kunopasa na 10 km.
20 capsules
20 kapsula
20 doses
20 doza:
20 injection needles
20 igala za injekciju
20 injection needles
injekciju
20 kg to less than 25 kg
20 kg do manje od 25 kg
20 kg to less than 25 kg
od 20 kg do manje od 25 kg
20 mg
tablete
20 mg docetaxel in 0.5 ml polysorbate 80 (40 mg/ml) Fill: 24.4 mg/0.61 ml
20 mg docetaksela u 0,5 ml polisorbata 80 (40 mg/ml) Punjenje: 24,4 mg/0,61 ml
20 mg eow
20 mg svaki drugi tjedan
20 mg film-coated tablets: Each film-coated tablet contains 1.89 mg lactose monohydrate.
Filmom obložene tablete od 20 mg: Jedna filmom obložena tableta sadrži 1,89 mg laktoze hidrata.
20 mg of lactose monohydrate per film-coated tablet For the full list of excipients, see section 6.1.
Za cjeloviti popis pomoćnih tvari, vidjeti dio 6.1.
20 mg once daily
20 mg jedanput dnevno
20 mg once daily
Na temelju tih
20 mg once daily
pojedinačna doza u
20 mg once daily on days 1-21, every 28 days
20 mg jednom dnevno od 1. do 21. dana, svakih 28 dana
20 mg orally once daily
20 mg peroralno jedanput na dan
20 mg per day).
20 mg na dan).
20 mg single dose
pojedinačna
20 mg subcutaneously once daily
20 mg supkutano jedanput na dan
20 mg tablets are white, round, flat with logo T on one side
Tablete od 20 mg su bijele, okrugle, plosnate s oznakom T na jednoj strani.
20 mg tablets once a day
tableta od 20 mg jedanput na dan
20 mg tablets once a day
tableta od 20 mg jednom dnevno
20 mg tablets: Robenacoxib 20 mg
20 mg tablete: robenakoksib 20 mg
20 mg twice daily
20 mg dva puta na dan
20 mg/kg body weight
20 mg/kg tjelesne težine
20 mg/kg/day
20 mg/kg/dan
20 mg/ml Robenacoxib
20 mg/ml robenakoksib
20 microgram
20 mikrograma
20 microgram dose peaked at 2.5 hours with a mean %ID/g of 0.0023%/g ± 0.0005%/g.
Doza od 20 mikrograma dosegnula je vrhunac nakon 2,5 sata s prosječnom %ID/g od 0,0023%/g ± 0,0005%/g.
20 microgram pen
Uporaba ljubičaste brizgalice od 20 mikrograma
20 microgram/ml up to 26 weeks did not cause any local irritation of the upper and lower respiratory tract.
20 mikrograma/ml do 26 tjedana nije uzrokovala nikakvu lokalnu nadraženost gornjeg i donjeg respiratornog trakta.
20 microgram/ml using the Breelib were 77% and 42%, respectively higher compared to inhalation of the same dose using Ventavis 10 microgram/ml and the I-Neb AAD system.
20 mikrograma/ml pomoću atomizatora Breelib bila je 77%, odnosno 42% veća u usporedbi s inhalacijom iste doze primjenom lijeka Ventavis 10 mikrograma/ml pomoću sustava I-Neb AAD.
20 microgram/ml with two coloured rings (yellow - red), is transferred into the medication chamber immediately before use.
20 mikrograma/ml označene s dva prstena u boji (žuti - crveni), premješta se u komoru za lijek neposredno prije primjene.
20 minutes approximately 20 % of the active compound flutemetamol (18F) remains in the circulation, falling to 10 % at 180 minutes.
20 minuta, otprilike 20% djelatne tvari flutemetamola (18F) ostaje u cirkulaciji, a nakon 180 minuta 10%.
20 ml
Otapalo: 20 ml
20 ml & 50 ml (EU/2/96/001/003, EU/2/96/001/004, EU/2/97/001/006 & EU/2/96/001/007)
20 ml i 50 ml (EU/2/96/001/003, EU/2/96/001/004, EU/2/97/001/006 & EU/2/96/001/007)
20 ml (10 doses) 100 ml (50 doses)
20 ml (10 doza) 100 ml (50 doza)
20 ml (10 doses) 50 ml (25 doses)
20 ml (10 doza) 50 ml (25 doza)
20 ml (10 doses) 50 ml (25 doses) 100 ml (50 doses)
20 ml (10 doza) 50 ml (25 doza) 100 ml (50 doza)
20 ml (10 doses) 50 ml (25 doses) 100 ml (50 doses)
20 ml (10 doza), 50 ml (25 doza), 100 ml (50 doza).
20 ml (10 doses) 50 ml (25 doses) 100 ml (50 doses) 200 ml (100 doses) 250 ml (125 doses)
20 ml (10 doza) 50 ml (25 doza) 100 ml (50 doza) 200 ml (100 doza) 250 ml (125 doza)
20 ml (10 doses), 50 ml (25 doses)
20 ml (10 doza), 50 ml (25 doza).
20 ml (10 doses), 50 ml (25 doses), 100 ml (50 doses)
20 ml (10 doza), 50 ml (25 doza), 100 ml (50 doza)
20 ml (40 doses)
20 ml (40 doza)
20 ml + 10 ml) Kuvan solution and transfer it to a glass or cup for administration).
20 ml + 10 ml) otopine Kuvana i prenijeli ih u čašu ili šalicu za primjenu.
20 ml bottle
20 ml u bočici
20 ml glass vial (Type 1) closed with a rubber (halobutyl) stopper and aluminium seal with flip-off cap.
Staklena bočica od 20 ml (tipa 1), zatvorena gumenim (halobutilnim) čepom i aluminijskim zaštitnim prstenom s "flip-off"zatvaračem.
20 ml glass vial type I, with a coated (B2-42) grey rubber stopper and a flip-off cap filled with powder for solution for injection.
Staklena bočica tipa I od 20 ml, s obloženim (B2-42) sivim gumenim čepom i «flip-off» poklopcem, napunjena praškom za otopinu za injekciju.
20 ml of water for injections in a glass vial (type I), closed with a rubber (chlorobutyl) stopper and an aluminium seal with a plastic flip off cap.
20 ml vode za injekcije u staklenoj bočici (staklo tip I) zatvorenoj gumenim (klorobutil) čepom i aluminijskim zatvaračem s plastičnom "flip off" kapicom.
20 ml Type I glass vial, closed with a grey butyl stopper and sealed with aluminium crimp seal with a polypropylene flip off button, containing either 300 mg or 400 mg elotuzumab.
Staklena bočica (staklo tipa I) od 20 ml, zatvorena sivim butilnim čepom i zapečaćena aluminijskim zaštitnim prstenom s polipropilenskom "flip-off" kapicom, koja sadrži 300 mg ili 400 mg elotuzumaba.
20 ml vial
20 ml bočica
20 ml vial
bočica 20 ml
20 ml vial labels (EU/2/96/001/003 & EU/2/96/001/006 only)
20 ml bočice s etiketom(EU/2/96/001/003i EU/2/96/001/006 samo)
20 ml Vial – 5 ml Vial
Bočica 20 mL – bočica 5 mL
20 ml, 100 ml or 200 ml bottles of Type I hydrolytic glass containing solvent for the 10-doses, 50- doses or 100-doses presentation or Type II glass rinsed with WFI containing solvent for the 50-doses and 100-doses presentation.
20 ml, 100 ml ili 200 ml bočice od hidrolitičkog stakla tipa I koje sadrže otapalo za pripremu 10, 50 ili 100 doza.
20 multidose vials (10 doses per vial – 0.5 ml per dose)
20 višedoznih bočica (10 doza po bočici – 0,5 ml po dozi)
20 November 2015
20. studenog 2015
20 November 2015
20. studenoga 2015.
20 packs, each containing 42 film-coated tablets.
20 pakiranja, svako sadrži 42 filmom obložene tablete.
20 packs, each containing 50 film-coated tablets.
20 pakiranja, svako sadrži 50 filmom obloženih tableta.
20 pipettes
20 pipeta
20 Placebo (N=57)
Placebo (N=57)
20 pre-filled syringe with 2 separate needles
20 napunjenih štrcaljki s 2 zasebne igle
20 pre-filled syringes
20 napunjenih štrcaljki
20 pre-filled syringes
EU/1/06/358/019
20 pre-filled syringes
štrcaljki
20 pre-filled syringes + 40 needles
štrcaljki + 40 igala
20 pre-filled syringes and 20 sterile needles
20 štrcaljki napunjenih pojedinačnom dozom i 20 sterilnih igala.
20 pre-filled syringes with 2 separate needles
20 napunjenih štrcaljki s 2 zasebne igle
20 pre-filled syringes without needle
20 napunjenih štrcaljki bez igle
20 psi (1.4 bar)
20 psi (1,4 bar)
20 sachets
20 vrećica
20 single dose vials, 0.5 ml each.
20 jednodoznih bočica, svaka 0,5 ml.
20 tablets
100 tablets
20 tablets
20 tablet
20 tablets.
20 tableta.
20 tablets: EU/1/08/469/001
20 tableta: EU/1/08/469/001
20 tablets: EU/1/08/469/006
20 tableta: EU/1/08/469/006
20 tablets: EU/1/08/469/011
20 tableta: EU/1/08/469/011
20 tablets: EU/1/08/469/016
20 tableta: EU/1/08/469/016
20 tablets: EU/1/08/469/021
20 tableta: EU/1/08/469/021
20 to 30 kg
20 do 30 kg
20 to < 25
20 do < 25
20 to < 40
20 do < 40
20 to <30 kg
20 do <30 kg
20 to <30 kg
od 20 do <30 kg
20 to less than 25
od 20 do manje od 25
20 tubes
20 tuba
20 vials
EU/1/06/358/008
20 vials + 20
20 bočica + 20
20 vials + 20 pre-filled syringes + 20 needles
20 bočica + 20 napunjenih štrcaljki + 20 igala
20 vials + 20 pre-filled syringes + 40 needles
20 bočica + 20 napunjenih štrcaljki + 40 igala
20 vials + 20 pre-filled syringes without needle
20 bočica + 20 napunjenih štrcaljki bez igle
20 vials and 20 pre-filled syringes
20 bočica i 20 napunjenih štrcaljki
20 vials and 20 pre-filled syringes + 40 needles
20 bočica i 20 napunjenih štrcaljki + 40 igala
20 VIALS AND 20 PRE-FILLED SYRINGES WITH 40 NEEDLES
20 BOČICA I 20 NAPUNJENIH ŠTRCALJKI SA 40 IGALA
20 VIALS AND 20 PRE-FILLED SYRINGES WITHOUT NEEDLES
20 BOČICA I 20 NAPUNJENIH ŠTRCALJKI BEZ IGALA
20 x 1 capsules
20 x 1 kapsula
20 x 1 dose (0.5 ml)
20 x 1 doza (0,5 ml)
20 x 1 film-coated tablet.
20 x 1 filmom obložena tableta
20 x 1 tablets
20 x 1 tableta
20 – 25 psi (1.4 – 1.7 bar)
20 – 25 psi (1,4 – 1,7 bar)
20% had metastatic prostate cancer
20% s metastatskim karcinomom prostate
20% of patients who received Hetlioz (8 out of 40) were able to adjust to the 24-hour clock after 1 months of treatment, compared with around 3% of patients on placebo (1 out of 38).
20% bolesnika koji su primili lijek Hetlioz (8 od 40) bilo je u stanju prilagoditi 24- satni ciklus tijekom 1 mjeseca terapije u usporedbi s otprilike 30% bolesnika koji su uzimali placebo (1 od 38).
20, 50, 100, 200 and 250 ml
20, 50, 100, 200 i 250 ml
20, rue Fleming B-1300 Wavre Belgium
20, rue Fleming B-1300 Wavre Belgija
20,000 birds with an average bodyweight of 50 g).
20 000 pilića prosječne mase 500 g).
20,000 birds with an average bodyweight of 50 g).
20 000 pilića prosječne težine 50 g).
20,000 birds with an average bodyweight of 500 g).
20 000 pilića prosječne mase 500 g).
20,000 birds with an average bodyweight of 500 g).
20 000 pilića prosječne težine 500 g).
20,000 doses
2000 doza
20,000 doses
20000 doza
20,000 IU/0.5 ml
20 000 IU/0,5 ml
20-120 mg
ritonavirom.
20-120 mg once daily5
20-120 mg jedanput na
20-40 Repeat every 12 to 24 hours, at least 1 day, until the bleeding episode as indicated by pain is resolved or healing achieved
20-40 Ponavljati svakih 12 do 24 sata tijekom najmanje 1 dana, dok se ne zaustavi krvarenje na koje upućuje bol ili do zacijeljenja.
20-40 Repeat every 12-24 hours.
20-40 Ponoviti svakih 12-24 sata.
20.0 % of patients treated with Herceptin subcutaneous formulation developed antibodies against the excipient hyaluronidase (rHuPH20).
U 20,0% bolesnika liječenih lijekom Herceptin u supkutanoj formulaciji razvila su se protutijela na pomoćnu tvar hijaluronidazu (rHuPH20).
20.0% of patients treated with Herceptin subcutaneous formulation developed antibodies against the excipient hyaluronidase (rHuPH20).
U 20,0% bolesnika liječenih lijekom Herceptin u supkutanoj formulaciji razvila su se protutijela na pomoćnu tvar hijaluronidazu (rHuPH20).
20.1 - 40
20,1 do 40
20.1 kg to 40 kg
20,1 kg do 40 kg
20.2 to 86.8
20,2 do 86,8
20.3 (18.1, NR)
20,3 (18,1; ND)
20.7 mo (17.6, 24,7)
20,7 mjeseci (17,6; 24,7)
20.7% respectively), gastrointestinal symptoms (9.3%, 9.4% and 8.3% respectively) and fever (8.0%,
20,7%), gastrointestinalni simptomi (9,3%, 9,4% odnosno 8,3%) i vrućica (8,0%, 5,3% odnosno
20.9 [15.7, 25.9] (n = 131)
Smrt ili progresija, n (%)
200 (2 x 100 mg or 4 x 50 mg)
200 (2 x 100 mg ili 4 x 50 mg)
200 (4 x 50) vaccinal baits.
200 (4 x 50) cjepnih mamaca
200 capsules
200 kapsula
200 doses
200 doza
200 film-coated tablets
200 filmom obloženih tableta
200 IU (400 IU/mL) recombinant follicle-stimulating hormone (FSH) activity.
200 IU (400 IU/ml) aktivnosti rekombinantnog folikulostimulirajućeg hormona (FSH).
200 IU/ml after reconstitution).
200 IU/ml nakon pripreme).
200 mcg/ 2 ml 400 mcg/ 4 ml 1000 mcg/ 10 ml
200 µg/ 2 ml 400 µg/ 4 ml 1000 µg/ 10 ml
200 mcg/0.3 ml
200 mcg/0,3 ml
200 mg (10 ml) once daily
200 mg (10 ml) jedanput na dan
200 mg (4 sachetsa)
200 mg (4 vrećicea)
200 mg (5 ml) twice daily
200 mg (5 ml) dvaput na dan
200 mg (purity of at least 98% IgG)
200 mg (čistoće najmanje 98% IgG)
200 mg (two 100 mg capsules) ritonavir twice per day with food.
200 mg (dvije kapsule od 100 mg) ritonavira dvaput dnevno s hranom.
200 mg capsules
Kapsule od 200 mg
200 mg every 2 weeks with MTX
200 mg svaka 2 tjedna s MTX-om
200 mg IgG............................................ ≥ 98%
200 mg IgG…………………... ≥ 98
200 mg once daily followed by 200 mg twice daily
200 mg jedanput na dan te potom 200 mg dvaput na dan
200 mg once daily for four days
200 mg jednom dnevno
200 mg once daily for four days
200 mg jednom dnevno tijekom 4 dana
200 mg once in the morning
200 mg jedanput ujutro
200 mg or 400 mg every 2 weeks with MTX
200 mg ili 400 mg svaka 2 tjedna s MTX-om
200 mg QD
Flukonazol 200 mg 1x/dan
200 mg three times a day
200 mg triput dnevno
200 mg twice a day
200 mg dvaput dnevno
200 mg twice daily
200 mg 2 puta dnevno
200 mg/50 mg tablets – Blister of 8 film-coated tablets or Blister of 12 film-coated tablets
200 mg/50 mg tablete – Blister s 8 filmom obloženih tableta ili blister s 12 filmom obloženih tableta
200 mg/50 mg tablets – Bottle label
200 mg/50 mg tablete – Naljepnica na boci
200 mg/50 mg tablets – Carton of 1 bottle
200 mg/50 mg tablete – kutija s 1 bocom
200 mg/50 mg/200 mg) tablets, Levodopa/Carbidopa/Entacapone Orion dosing should be carefully titrated for optimal clinical response.
150 mg/37,5 mg/200 mg ili 200 mg/50 mg/200 mg) tabletama, doziranje Levodopa/Carbidopa/Entacapone Oriona mora biti pažljivo titrirano radi optimalnog kliničkog odgovora.
200 mg/50 mg/200 mg) tablets, Levodopa/Carbidopa/Entacapone Orion dosing should be carefully titrated for optimal clinical response.
175 mg/43,75 mg/200 mg ili 200 mg/50 mg/200 mg) tabletama, doziranje Levodopa/Carbidopa/Entacapone Oriona mora biti pažljivo titrirano radi optimalnog kliničkog odgovora.
200 mg/50 mg/200 mg) tablets, Levodopa/Carbidopa/Entacapone Orion dosing should be carefully titrated for optimal clinical response.
Levodopa/Carbidopa/Entacapone Oriona mora biti pažljivo titrirano radi optimalnog kliničkog odgovora.
200 mg/8 ml 1 vial
200 mg/8 ml 1 bočica
200 mg/day.Patients whose dose of Ribavirin Teva Pharma B.V. is reduced to 600 mg daily receive one 200 mg tablet in the morning and two 200 mg tablets in the evening.
Bolesnici kojima je doza lijeka Ribavirin Teva Pharma B.V. smanjena na dnevnu dozu od 600 mg uzimaju jednu tabletu od 200 mg ujutro i dvije tablete od 200 mg navečer.
200 mg/kg feed) reduced lung lesions, improved clinical signs and pig growth rates.
200 mg/kg hrane) smanjilo je lezije na plućima, poboljšalo kliničke znakove i stope rasta svinja.
200 mg/m2 intravenous
200 mg/m2 intravenski/2
200 mg/ml fenbendazole
200 mg/ml fenbendazola
200 mg/stavudine 40 mg, both
200 mg/stavudin 40 mg, oba u
200 mg/tenofovir disoproxil (as fumarate) 245 mg (E/C/F/TDF) (n = 867) once daily.
150 mg/emtricitabin 200 mg/tenofovirdizoproksil (u obliku fumarata) 245 mg (E/C/F/TDF) (n = 867) jednom dnevno.
200 microgram tablets.
200 mikrograma.
200 micrograms
(0,17-1,60)
200 micrograms
200 mikrograma
200 micrograms / dose
200 mikrograma / doza
200 micrograms fentanyl (as citrate)
200 mikrograma fentanila (u obliku fentanilcitrata)
200 micrograms labelling is greenish-blue.
200 mikrograma označeno je zelenkastoplavo.
200 micrograms PRE-FILLED SYRINGES LABEL
NALJEPNICA ZA NAPUNJENU ŠTRCALJKU 200 mikrograma
200 micrograms/dose labelling is greenish-blue.
200 mikrograma/doza, označeno je zelenkastoplavo.
200 ml
10 x 200 ml
200 ml 100 % orange juice or
200 ml 100%-tnog soka od naranče ili
200 ml and 465 ml amber glass bottles with white polypropylene screw cap and a measuring cup.
Smeđe staklene boce od 200 ml i 465 ml s bijelim polipropilenskim zatvaračem s navojem i odmjernom čašom.
200 ml syrup with measuring cup 465 ml syrup with measuring cup
200 ml sirup s odmjernom čašom 465 ml sirup s odmjernom čašom
200 mL/hour
200 ml/h
200 q12h 100 q12h ↓ 39% ↓ 24%
100 svakih 12h ↓ 39% ↓ 24
200 q12h 100 q12h ↓ 39% ↓ 24%
200 svakih 12h 100 svakih 12h ↓ 39% ↓ 24
200 q12h, 13 days ↑ 22% 
200 svakih 12h, 13 dana
200 q12h/ co- administered 200 q12h/6h after
200 svakih 12h/ istodobna primjena
200 q12h/ co- administered 200 q12h/6h after
200 svakih 12h/ istodobna primjena 200 svakih 12h/6h kasnije
200 q12h/1h before
200 svakih 12h/1h prije
200 tablets
200 tablete
200 tablets
EU/1/13/891/015
200 to <350
200 do < 350
200 U/kg  500 U/vial × 70 kg = 28 vials
200 U/kg  500 U/bočica × 70 kg = 28 bočica
200 μg/2ml
200 μg/2 ml
200-300 mg/day orally (100-200 mg/day for paediatric patients) is recommended for chronic renal failure patients whose serum ferritin levels are below 100 ng/ml oral iron substitution of 200-300 mg/day is recommended for all cancer patients whose transferrin saturation is below 20%.
200-300 mg/dnevno oralno (100-200 mg/dnevno za pedijatrijske bolesnike) preporučuje se kod bolesnika s kroničnim zatajenjem bubrega čije su vrijednosti feritina ispod 100 ng/ml nadoknada željeza 200-300 mg/dnevno preporučuje se svim bolesnicima s malignim bolestima kod kojih je zasićenje transferina ispod 20%.
200-300 mg/day orally (100-200 mg/day for paediatric patients) is recommended for chronic renal failure patients whose serum ferritin levels are below 100 ng/ml oral iron substitution of 200-300 mg/day is recommended for all cancer patients whose transferrin saturation is below 20%.
200-300 mg/dnevno peroralno (100-200 mg/dnevno za pedijatrijske bolesnike) preporučuje se kod bolesnika s kroničnim zatajenjem bubrega čije su vrijednosti feritina ispod 100 ng/ml nadoknada željeza 200-300 mg/dnevno preporučuje se svim bolesnicima s malignim bolestima kod kojih je zasićenje transferina ispod 20%.
2000 doses
2000 doza:
2000 International Units/vial simoctocog alfa (800 IU/ml after reconstitution)
2000 međunarodnih jedinica simoktokog alfa po bočici (800 IU/ml nakon rekonstitucije)
2000 IU
2000 UI
2000 IU (octocog alfa) (400 IU/mL after reconstitution).
2000 IU (oktokoga alfa) (400 IU/ml nakon pripreme za primjenu).
2000 IU moroctocog alfa for single IV use
2000 IU moroktokoga alfa za jednokratnu i.v. primjenu
2000 IU octocog alfa
2000 IU oktokoga alfa
2000 IU octocog alfa (400 IU/ml after reconstitution).
2000 IU oktokoga alfa (400 IU/ml nakon pripreme za primjenu).
2000 IU/0.5 ml
2 000 IU/0,5 ml
2000 IU/1.0 ml
2000 IU/1,0 ml
2000 IU/vial
2000 IU po bočici
2000 mg/day
2000 mg/da n
2000 mg/day
2000 mg/dan
2000 Rockford Road, Charles City, IA 50616 USA
2000 Rockford Road, Charles City, IA 50616, SAD
20000 IU/0.5 m
20000 IU/0,5 ml
20000 IU/0.5 ml
10000 IU/1 ml
20000 IU/0.5 ml
40000 IU/1 ml
20000 IU/1.0 ml
Eporatio
2006 Jun 15;12:3782-91]
15. lipnja 2006.;12:3782-91]
20060 Pessano con Bornago (MI) Italy
20060 Pessano con Bornago (MI) Italija
2012.
tržište.
20148 Milan Italy
20148 Milano Italija
2016), and in addition, this interaction has also been described in an article by Shinoda et al., Biomed Tep 2016.
2016), a osim toga, ova interakcija također je opisana u članku Shinoda et al., Biomed Tep 2016.
2018, Q4 2020, and
2016, Q4 2018,
2021
Konačno
2031 BN Haarlem The Netherlands
2031BN Haarlem Nizozemska
2031 GA Haarlem Netherlands
ROK VALJANOSTI
2031 GA Haarlem Netherlands Manufacturer
2031 GA Haarlem Nizozemska
2031 GA Haarlem The Netherland
2031 GA Haarlem Nizozemska
2031 GA Haarlem, Netherlands
2031 GA Haarlem Nizozemska
2031 GA, Haarlem, The Netherlands
2031 GA, Haarlem, Nizozemska
20485, Sector 2, Bucureşti, RomâniaTel.: +40
20485, Sector 2, Bucureşti, România
205 Alewife Brook Parkway, Cambridge, Massachusetts 02138 USA
205 Alewife Brook Parkway, Cambridge, Massachusetts 02138 SAD
208 weeks in the Aldurazyme/Aldurazyme group and 182 weeks in the Placebo/Aldurazyme group as indicated in the table below.
208. tjedna u skupini Aldurazyme/Aldurazyme odnosno do 182. tjedna u placebo/Aldurazyme skupini, kao što je prikazano u tablici koja slijedi.
20ml
doza)
20–40 Repeat every 12 to 24 hours.
20 – 40 Ponovite svakih 12 – 24 sati najmanje
21 (mg/mL, concentration of reconstituted solution)
21 (mg/ml, koncentracija rekonstituirane otopine)
21 additional subjects received one dose of the vaccine virus at 107.5 TCID50, with 19 of those subjects receiving a second dose 4-8 weeks later.
Dodatnih 21 ispitanika primilo je jednu dozu cjepiva od 107,5 TCID50, od čega je 19 ispitanika primilo drugu dozu nakon 4 do 8 tjedana.
21 ART-experienced HIV-1 infected paediatric patients aged from 3 to < 6 years and weighing 10 kg to < 20 kg (16 participants from 15 kg to < 20 kg) who received PREZISTA oral suspension with low dose ritonavir twice daily in combination with other antiretroviral agents.
21 pedijatrijski bolesnik u dobi od 3 do < 6 godina i težine od 10 kg do < 20 kg (16 ispitanika imalo je od 15 kg do < 20 kg), prethodno liječeni ART-om, a inficirani su virusom HIV-1 te su primali PREZISTA oralnu suspenziju s niskom dozom ritonavira dva puta na dan u kombinaciji s drugim antiretrovirusnim lijekovima.
21 capsules
21 kapsula
21 Days after 1st Dose 2nd Dose
21 dan kasnije
21 days after 1st dose N=55
21 dan nakon
21 days after 1st dose N=925
21 dan nakon
21 Days after 21 Days after
21 dan kasnije 21 dan kasnije
21 days after 2nd dose N=128
Studija V87P13 21 dan nakon 2. doze
21 days after 2nd dose N=143
Studija V87P13 21 dan nakon 2. doze
21 days after 2nd dose N=149
21 dan nakon 2. doze N=149
21 days after 2nd dose N=149
Studija V87P1 21 dan nakon . doze
21 days after 2nd dose N=182
Studija V87P11 21 dan nakon . doze
21 days after 2nd dose N=197
Studija V87P13 21 dan nakon 2. doze
21 days after 2nd dose N=30
21 dan nakon 2. doze N=30
21 days after 2nd dose N=37
21 dan nakon 2. doze N=37
21 days after 2nd dose N=66
Studija V87P13 21 dan nakon 2. doze
21 days after 2nd dose N=69
Studija V87P13 21 dan nakon . doze
21 days after 2nd dose N=69
Studija V87P13 21 dan nakon 2. doze
21 days after 2nd dose N=70
21 dan nakon 2. doze N=70
21 days after 2nd dose N=84
21 dan nakon 2. doze N=84
21 days.
21 dan.
21 hard capsules
21 kapsula
21 hard capsules
21 tvrda kapsula
21 hard capsules.
21 tvrda kapsula
21 mg/kg twice daily
21 mg/kg dva puta na dan
21 month.
21 mjesec.
21 out of 63 (33%) patients treated with eltrombopag who were taking an ITP medicinal product at baseline permanently discontinued all baseline ITP medicinal products.
21 od 63 (33%) bolesnika liječenih eltrombopagom koji su uzimali druge lijekove za liječenje ITP na početku ispitivanja, trajno je prekinulo sve prethodno liječenje za ITP.
21 pipettes
21 pipeta
21 PTPs remained on the extended 14 day prophylaxis interval for additional treatment duration of 98 to 575 (median 386) days.
21 prethodno liječeni bolesnik ostao je na produljenom 14- dnevnom intervalu profilakse zbog dodatnog trajanja liječenja od 98 do 575 (medijan 386) dana.
21 September 2009
21. rujna 2009.
21 tablets
21 tableta
21 x 20 mg capsules (60 mg/day dose for a 7-day supply)
21 kapsulu od 20 mg (dnevna doza od 60 mg za primjenu tijekom 7 dana)